Literature DB >> 27720581

Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.

Maria Rita Bongiorno1, Nunzio Crimi2, Salvatore Corrao3, Alberto Allotta4, Antonino Arena5, Ignazio Brusca6, Enrico Heffler2, Giovanna Malara7, Mirella Milioto4, Giuseppe Pistone8, Morena Porto2, Emilio Raia9, Giuseppe Valenti10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27720581     DOI： 10.1016/j.anai.2016.08.006

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  5 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

Review 2.  Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Authors:  Susanne Radonjic-Hoesli; Kathrin Scherer Hofmeier; Sara Micaletto; Peter Schmid-Grendelmeier; Andreas Bircher; Dagmar Simon
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.

Authors:  Jacqueline Eghrari-Sabet; Ellen Sher; Abhishek Kavati; Dominic Pilon; Maryia Zhdanava; Maria-Magdalena Balp; Patrick Lefebvre; Benjamin Ortiz; Jonathan A Bernstein
Journal:  Allergy Asthma Proc       Date:  2018-02-19       Impact factor: 2.587

4.  Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.

Authors:  Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez
Journal:  World Allergy Organ J       Date:  2019-02-23       Impact factor: 4.084

5.  Omalizumab for urticaria treatment in clinical practice: a case series.

Authors:  Aleksandra Lesiak; Igor A Bednarski; Anna Maćkowska; Zuzanna Łukasik; Anna Woźniacka; Irmina Olejniczak-Staruch; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2018-08-21       Impact factor: 1.837
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.